Shahnaz Ahmed, MD
Internal Medicine · Bradenton, FLNPI 1780681049
Payments from drug & device makers
Across 369 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$981
- Lilly USA, LLC$660
- GSK$654
- AbbVie$615
- Pfizer$601
- Amgen$533
- plus $2K from 36 others
What the payments were for
- Food & beverage$6,45399%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $981 |
| Lilly USA, LLC | 38 | $660 |
| GSK | 45 | $654 |
| AbbVie(2 entities) | 37 | $615 |
| Pfizer | 34 | $601 |
| Amgen | 34 | $533 |
| AstraZeneca | 13 | $271 |
| Novartis | 14 | $255 |
| Bayer | 10 | $204 |
| Abbott | 10 | $188 |
| Daiichi Sankyo Inc. | 7 | $143 |
| Boehringer Ingelheim | 8 | $131 |
| Merck | 9 | $130 |
| Astellas Pharma US Inc | 3 | $110 |
| Philips North America LLC | 6 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $101 |
| Amarin Pharma, Inc. | 4 | $81 |
| Johnson & Johnson | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Shield Therapeutics Inc | 3 | $55 |
| Exact Sciences | 2 | $45 |
| Dexcom, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $30 |
| Boston Scientific | 1 | $24 |
| Abiomed | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Inari Medical, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Medtronic | 1 | $14 |
| Nevro Corp. | 1 | $14 |
| Linus Health, Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
How this compares
$6,528 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $206,581 |
| EliquisApixaban | 189 | $205,811 |
| JardianceEmpagliflozin | 111 | $150,426 |
| MounjaroTirzepatide | 130 | $148,174 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 111 | $97,844 |
| FarxigaDapagliflozin Propanediol | 59 | $84,783 |
| XareltoRivaroxaban | 38 | $52,841 |
| Repatha SureclickEvolocumab | 47 | $48,955 |
| Repatha SyringeEvolocumab | 60 | $44,209 |
| RybelsusSemaglutide | 15 | $41,266 |
| MyrbetriqMirabegron | 51 | $40,415 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $22,321 |
| JanuviaSitagliptin Phosphate | 20 | $18,620 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $16,523 |
| TradjentaLinagliptin | 21 | $15,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $981 | $247,846170 claims |
| PfizerEliquis | $601 | $205,811189 claims |
| Boehringer IngelheimJardiance, Tradjenta | $131 | $166,273132 claims |
| Lilly USA, LLCMounjaro | $660 | $148,174130 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $654 | $109,844131 claims |
| AstraZenecaFarxiga | $271 | $84,78359 claims |
| Johnson & JohnsonXarelto | $76 | $52,84138 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua) | $130 | $41,17152 claims |
| Astellas Pharma US IncMyrbetriq | $110 | $40,41551 claims |
| AbbVieSynthroid, Armour Thyroid | $615 | $9,991134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Bradenton
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.